3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Lymphoid
1
Conditions
Vascular Diseases
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Cardiovascular Diseases
1
Blood Protein Disorders
1
Interventions
Dexamethasone
3
Bortezomib
3
pomalidomide
2
isatuximab
2
trametinib
1
ricolinostat
1
ficlatuzumab
1
dabrafenib
1
cobimetinib
1
Vorinostat
1
Vemurafenib
1
Ranitidine
1
Lenalidomide
1
Erlotinib Hydrochloride
1
Diphenhydramine
1
Cyclophosphamide
1
Acetaminophen
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
ficlatuzumab
×
Plasma cell
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled